Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Diabetes

Journal Scan / Research · April 21, 2016

Ranolazine as Secondary Agent in Type 2 Diabetes Treatment

Diabetes, Obesity & Metabolism

 

Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Effect of Ranolazine on Glycaemic Control in Patients With Type 2 Diabetes Treated With Either Glimepiride or Metformin
Diabetes Obes Metab 2016 May 01;18(5)463-474, J Pettus, B McNabb, RH Eckel, JS Skyler, A Dhalla, S Guan, P Jochelson, L Belardinelli, RH Henry

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading